NasdaqGS:DXCMMedical Equipment
Does DexCom’s (DXCM) Longer-Wear G7 Approval Hint At A Durable Edge In Connected Diabetes Care?
In July 2026, DexCom, Inc. received Health Canada authorization for its Dexcom G7 15 Day Continuous Glucose Monitoring System for adults with diabetes, offering up to 15.5 days of wear, best-in-class accuracy with an overall MARD of 8.0%, and multiple app-based connectivity and data-sharing features.
This approval not only extends DexCom’s CGM presence in Canada but also underscores how longer wear duration and fewer sensor changes may strengthen its competitive position in digitally...